Cellestial Health raises pre-seed funding led by Zinc VC to advance its astrocyte-targeted drug development for brain disorders.

May 09, 2025•7 months ago

Round Type

Pre-Seed

CambridgeTherapeuticsBiotechnologyHealth Care

Investors

Alma AngelsSfc CapitalZinc Vc

Description

Cellestial Health has successfully raised pre-seed funding, led by Zinc VC and supported by SFC Capital and Angel investors. The funding will help develop innovative treatments targeting astrocytes for neurodegenerative diseases. Additionally, the company received £340k in grant funding from Parkinson’s UK and Cambridge Enterprise. Their approach seeks to revolutionize brain disorder treatments by restoring normal astrocytic functions.

Company Information

Company

Cellestial Health

Location

Cambridge, England, United Kingdom

About

Cellestial Health is focused on revolutionizing the treatment of brain disorders by incorporating astrocytes into drug development. The company aims to develop brain-permeable small molecule drugs that restore normal astrocytic network function, offering a new pathway for neurodegenerative conditions like Parkinson's disease. Built on years of academic research, Cellestial validates its drug targets and collaborates with leading drug discovery experts to advance its innovative therapeutics. Their mission addresses the urgent need for treatments that go beyond symptom management in neurodegenerative diseases.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns